Vorasidenib [VOR1]

For treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in patients aged 12 years and over where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant, or internally accredited oncology specialty trainee, specifically trained and assessed in the use of systemic anti-cancer therapy.
2. The patient has a documented, histologically confirmed, diagnosis of Grade 2 oligodendroglioma or astrocytoma, and is 12 years of age or older.
3. This cancer has a susceptible isocitrate dehydrogenase (IDH) 1 or IDH2 mutation.
4. The patient must have had at least one prior surgery, but no other prior anticancer treatments (chemotherapy or radiation).
5. The patient has an ECOG performance status of 0 or 1 or, if using the Karnofsky/Lansky score, this is 80 or higher.
6. The patient has been assessed as NOT requiring immediate treatment with chemotherapy OR radiotherapy (i.e. in the absence of vorasidenib, would be suitable for a “watch and wait approach”).
7. The patient does not currently exhibit any of the “high risk” features described below • Uncontrolled seizures • Brain-stem involvement • Clinically relevant functional or neurocognitive deficits caused by the tumour • Glucocorticoid use for glioma-related signs or symptoms
8. Vorasidenib will continue until unacceptable toxicity, withdrawal of patient consent, or progression of disease, whichever of these events occurs first.
9. Where a treatment break of more than 6 weeks beyond the expected 4-weekly cycle length is needed, a treatment break approval form will be completed to restart treatment, which MUST be approved before treatment with vorasidenib is recommenced.
10. Vorasidenib will otherwise be used as set out in its Summary of Product Characteristics (SPC).

CDF funded From: 31 March 2026

Additional information

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Note

The data on this page was produced using version 1.394 of the CDF list, downloaded from NHS England’s website on 24 April 2026 at 18:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.